Cetera Investment Advisers
LXRX icon

Cetera Investment Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cetera Investment Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Sell
10,524
-2,109
-17% -$4.11K ﹤0.01% 4833
2026
Q1 		$19.7K Sell
12,633
-1,555
-11% -$2.26K ﹤0.01% 4660
2025
Q4 		$16.3K Sell
14,188
-3,336
-19% -$4.58K ﹤0.01% 4588
2025
Q3 		$23.7K Buy
+17,524
New +$19.9K ﹤0.01% 4480
2024
Q4 		– Sell
-21,775
Closed -$34.2K – 3845
2024
Q3 		$34.2K Buy
+21,775
New +$38.8K ﹤0.01% 3624
2024
Q2 		– Sell
-10,675
Closed -$25.6K – 3809
2024
Q1 		$25.6K Buy
+10,675
New +$22.9K ﹤0.01% 3620
2021
Q2 		– Sell
-20,689
Closed -$121K – 1802
2021
Q1 		$121K Buy
+20,689
New +$143K ﹤0.01% 1541

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cetera Investment Advisers's LXRX Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Lexicon Pharmaceuticals (LXRX) stake by 17% in Q2 2026, selling an estimated $4.11K and leaving 10,524 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4833.

Cetera Investment Advisers first reported a position in LXRX in Q1 2021 and has held it in 7 quarters since. The position peaked at $121K in Q1 2021. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Cetera Investment Advisers held 10,524 shares of Lexicon Pharmaceuticals worth $25.3K as of Q2 2026.
  • Cetera Investment Advisers sold 2,109 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $4.11K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4833 holding.
  • Cetera Investment Advisers first reported a position in Lexicon Pharmaceuticals in Q1 2021 and has held it in 7 quarters since.
  • Cetera Investment Advisers's Lexicon Pharmaceuticals position peaked at $121K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.